These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 3553333)

  • 1. Purification of C1 inhibitor. A new approach for the isolation of this biologically important plasma protease inhibitor.
    Prograis LJ; Hammer CH; Katusha K; Frank MM
    J Immunol Methods; 1987 May; 99(1):113-22. PubMed ID: 3553333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new simplified procedure for C1 inhibitor purification. A novel use for jacalin-agarose.
    Pilatte Y; Hammer CH; Frank MM; Fries LF
    J Immunol Methods; 1989 Jun; 120(1):37-43. PubMed ID: 2732474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification of a proteinase inhibitor from bovine serum with C1-inhibitor activity.
    Van Nostrand WE; Cunningham DD
    Biochim Biophys Acta; 1987 Feb; 923(2):167-75. PubMed ID: 3814612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C1 inhibitor.
    Davis AE; Aulak KS; Zahedi K; Bissler JJ; Harrison RA
    Methods Enzymol; 1993; 223():97-120. PubMed ID: 8271970
    [No Abstract]   [Full Text] [Related]  

  • 5. Variability in purified dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema. Functional and analytical gel studies.
    Donaldson VH; Harrison RA; Rosen FS; Bing DH; Kindness G; Canar J; Wagner CJ; Awad S
    J Clin Invest; 1985 Jan; 75(1):124-32. PubMed ID: 3965500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of plasma kallikrein and C1-s with normal and dysfunctional C1(-)-inhibitor proteins from patients with hereditary angioneurotic edema: analytic gel studies.
    Donaldson VH; Wagner CJ; Tsuei B; Kindness G; Bing DH; Harrison RA; Rosen FS
    Blood; 1987 Apr; 69(4):1096-101. PubMed ID: 3493816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human C1 inhibitor: improved isolation and preliminary structural characterization.
    Harrison RA
    Biochemistry; 1983 Oct; 22(21):5001-7. PubMed ID: 6416294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor J: isolation and characterization of a new polypeptide inhibitor of complement C1.
    Lopez-Trascasa M; Bing DH; Rivard M; Nicholson-Weller A
    J Biol Chem; 1989 Sep; 264(27):16214-21. PubMed ID: 2476439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modification of an affinity procedure for purification of human C1- inhibitor that provides a homogeneous stable preparation.
    Donaldson VH; Falconieri MW
    J Immunol Methods; 1993 Jan; 157(1-2):101-4. PubMed ID: 8423351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified methods for the purification, quantitation, and functional estimation of human complement C-1-inhibitor (C-1-INH) with a monoclonal anti-C-1-INH antibody.
    Alsenz J; Loos M
    J Immunol Methods; 1987 Jan; 96(1):107-14. PubMed ID: 3805729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C1-inhibitor prevents PEG fractionation-induced, EDTA-resistant activation of mouse complement.
    van den Berg CW; Aerts PC; van Dijk H
    Mol Immunol; 1992 Mar; 29(3):363-9. PubMed ID: 1372956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first component of complement. I. Purification and properties of native C1.
    Medicus RG; Chapuis RM
    J Immunol; 1980 Jul; 125(1):390-5. PubMed ID: 7381205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.
    Schapira M; Scott CF; Colman RW
    J Clin Invest; 1982 Feb; 69(2):462-8. PubMed ID: 6173399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of C1 inhibitor upon Hageman factor autoactivation.
    Weiss R; Silverberg M; Kaplan AP
    Blood; 1986 Jul; 68(1):239-43. PubMed ID: 3487356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Isolation and purification of pregnancy-associated plasma protein A].
    Suzuki Y; Takada J; Isaka K; Takayama M; Grudzinskas JG
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Jan; 48(1):17-24. PubMed ID: 8576617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New preparation method of C1 esterase for the dosage of its plasma inhibitor].
    Gozin D; Ollier-Hartmann MP; Lerable J; Hartmann L; Soulier JP
    Biomed Pharmacother; 1983; 37(5):228-30. PubMed ID: 6607074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro interaction of C1-inhibitor with thrombin.
    Cugno M; Bos I; Lubbers Y; Hack CE; Agostoni A
    Blood Coagul Fibrinolysis; 2001 Jun; 12(4):253-60. PubMed ID: 11460008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromatographic procedure for preparation of a high-purity C 1 esterase inhibitor concentrate.
    Benny AG; Brimer CM
    J Chromatogr; 1988 Dec; 433():363-6. PubMed ID: 3235568
    [No Abstract]   [Full Text] [Related]  

  • 19. Evaluation of the chromatographic procedure for the preparation of a high-purity C1-esterase inhibitor concentrate from cryosupernatant plasma.
    Teh LC; Froger M
    J Chromatogr; 1992 Nov; 582(1-2):65-70. PubMed ID: 1491059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-scale preparation of highly purified human C1-inhibitor for therapeutic use.
    Poulle M; Burnouf-Radosevich M; Burnouf T
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):543-9. PubMed ID: 7841310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.